Patents by Inventor S. Richard Jaskunas

S. Richard Jaskunas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding a novel penicillin binding protein from streptococcus pneumoniae
    Patent number: 5789202
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel high molecular weight PBP of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the PBP and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the PBP.
    Type: Grant
    Filed: October 17, 1996
    Date of Patent: August 4, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, S. Richard Jaskunas, Jr., Pamela K. Rockey, Paul R. Rosteck, Jr., Franklin H. Norris
  • Methods of using recombinant human protein C
    Patent number: 5151268
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: September 29, 1992
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Vectors and compounds for direct expression of activated human protein C
    Patent number: 4992373
    Abstract: A method for the direct recombinant production of activated protein C is described. DNA compounds, vectors, and transformants useful in the method are also disclosed. The method involves transformation and culture of a host cell with a recombinant DNA vector that encodes a protein C molecule in which the activation peptide is replaced with a cleavage sequence for a cell associated protease.
    Type: Grant
    Filed: December 4, 1987
    Date of Patent: February 12, 1991
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Hartmut Ehrlich, Brian W. Grinnell, S. Richard Jaskunas
  • Expression vectors for use in E. coli
    Patent number: 4874703
    Abstract: The present invention provides a transcriptional and translational activating sequence derived from the lambda pL transcriptional activating sequence and the E. coli lpp translational activating sequence. The activating sequence has been cloned into recombinant DNA expression vectors into which DNA sequences encoding funtional polypeptides can be readily inserted and expressed. The activating sequence of the present invention has been shown to drive high-level expression of a bovine growth hormone derivative and a human growth hormone derivative in E. coli. Preferred expression vectors of the present invention also comprise the cI857 temperature-sensitive lambda pL repressor gene, a rop.sup.- derivative of the plasmid pBR322 replicon, and a tetracycline resistance-conferring gene.
    Type: Grant
    Filed: August 26, 1985
    Date of Patent: October 17, 1989
    Assignee: Eli Lilly and Company
    Inventor: S. Richard Jaskunas
  • Vectors and compounds for expression of human protein C
    Patent number: 4775624
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: February 8, 1985
    Date of Patent: October 4, 1988
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Shelia P. Little, George L. Long, Robert F. Santerre
  • Penicillin binding protein from Streptococcus pneumoniae
    Patent number: H2085
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel high molecular weight PBP of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the PBP and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the PBP.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: October 7, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, S. Richard Jaskunas, Jr., Genshi Zhao, Pamela K. Rockey, Paul R. Rosteck, Jr., Franklin H. Norris